Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings.
Vol 23, No 16S (June 1 Supplement), 2005: 503
© 2005 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Budd, G. T. Articles by Hayes, D. F. Search for Related Content PubMed Articles by Budd, G. T. Articles by Hayes, D. F.

Abstract

Monitoring circulating tumor cells (CTC) in non-measurable metastatic breast cancer (MBC)

Cleveland Clinic Fdn, Cleveland, OH; MD Anderson Cancer Ctr, Houston, TX; Washington Univ, St Louis, MO; Univ of Arizona, Tucson, AZ; Immunicon Corp, Philadelphia, PA; Immunicon, Philadelphia, PA; Univ of Michigan, Ann Arbor, MI

503

Background: We have previously reported that the presence of 5 or more circulating tumor cells (CTCs) in 7.5 mL of blood from women with measurable disease in metastatic breast cancer (MBC) is associated with a poor outcome (NEJM, 351:8, 781–791, 2004). Here we report the results of the CTC assay in 46 MBC patients with non measurable disease. Methods: CTCs were enumerated in 7.5mL whole blood at baseline and at 3 or 4 week follow-up intervals for a period of six months in 46 patients with non measurable MBC about to start a new systemic therapy. CTCs were immunomagnetically separated and fluorescently labeled using the CellSearch Kit. Only nucleated (DAPI+) cells with the phenotype EpCAM+, Cytokeratin 8, 18 and/or 19+, and CD45- were counted using the CellSpotter Analyzer. Results: Median Progression Free Survival (PFS) and Overall Survival (OS) were determined for patients with <5 or 5 CTC /7.5mL at baseline and at first follow-up. The percentage of patients that were alive at 12 months (AL12) after the blood draw, the frequency of patients with 5 or more CTCs and the significance between the two groups of patients (logrank) is indicated in the table below. Conclusions: Data relating the presence of CTCs in non-measurable MBC with PFS and OS were similar to the data previously reported for measurable MBC. The presence of CTC in MBC patients can be used as a surrogate marker for PFS and OS in MBC patients with non-measurable as well as measurable disease.

View larger version (13K): [in this window] [in a new window]

Abstract presentation from the 2005 ASCO Annual Meeting